Indoco Remedies share news and announcements
NSE: INDOCOBSE: 532612Pharmaceuticals & BiotechnologySmall Cap
Last close ₹226.50up ₹0.90 (0.40%)BSE ₹227.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹225.60.
52-week range of traded prices to 23 Oct 2026
₹162.19Low, 30 Mar 2026₹291.00High, 23 Oct 2025
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,091 Cr1,173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 28 Jul 2026
- 371.3
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹94 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 7 May 2026
- 2.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.09%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 28 Jul 2026
- 0.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹94 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −9.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 28 Jul 2026
- 1.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 7 May 2026
- 1.11
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,58,87951.2% delivered
Indoco Remedies board meetings
103 filed, newest first. Page 1 of 3.
Oct 2026
Jul 2026
Apr 2026
Jan 2026
Oct 2025
Jul 2025
May 2025
Jan 2025
Oct 2024
Jul 2024
May 2024
16 May · Board meeting
Jan 2024
23 Jan · Board meeting
Oct 2023
19 Oct · Board meeting
Jul 2023
May 2023
23 May · Board meeting
23 May · Board meeting
Jan 2023
Oct 2022
Jul 2022
May 2022
Apr 2022
Jan 2022
Oct 2021
Jul 2021
May 2021
Jan 2021
Oct 2020
Jul 2020
Jun 2020
Jan 2020
Oct 2019
Jul 2019
May 2019
Jan 2019
Oct 2018
Jul 2018
4 Jul · Board meeting
To consider and approve the financial results for the period ended Jun 30, 2018 (opens in a new tab)Not held on this date
May 2018
Jan 2018
Oct 2017
Jul 2017
May 2017
Jan 2017
Oct 2016
Jul 2016
May 2016